Madeline Louise Singer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Madeline Louise Singer has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Kenneth Bo Foreman
Department of Physical Therapy, The University of Utah, Salt Lake City, UT, USA
2 shared publications Leland E. Dibble
Department of Physical Therapy University of Utah 520 Wakara Way Salt Lake City Utah
2 shared publicationsAnil Wadhwani
Neurology Department University of Pennsylvania Philadelphia Pennsylvania USA
1 shared publicationBandhu Paudyal
WellSpan Neurology WellSpan Health Ephrata Pennsylvania USA
1 shared publication- Chafic Karam
Department of Neurology University of Pennsylvania Philadelphia Pennsylvania USA
1 shared publication - Colin Quinn
Neuromuscular Division, Neurology Department, University of Pennsylvania, Philadelphia, PA
1 shared publication
Latest Publications
- 26 November 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (10) , e209848
Pearls & Oy-sters: Breaking Bad CIDP
- 26 November 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (10) , e209848
Pearls & Oy-sters: Breaking Bad CIDP
- 21 November 2023
- Published by Wiley in Muscle & Nerve
- Vol. 69 (1) , 87-92
Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse events
Introduction/Aims: Efgartigimod is a neonatal Fc receptor blocker and was the first approved medication in its class for the treatment of generalized myasthenia gravis (gMG). As a novel therapy, little is known about the use of efgartigimod in clinical practice. This study aims to describe how efgartigimod is being incorporated into the current therapeutic landscape of MG.Methods: We reviewed the charts of 17 patients with gMG treated with efgartigimod at the University of Pennsylvania between January 2022 and June 2023.Results: Efgartigimod was selected mainly for patients who were treatment refractory, had side effects to other treatments, and/or required quick improvement in their symptoms. All patients had been previously treated with at least one medication for MG and had an average baseline Myasthenia Gravis Activities of Daily Living (MG‐ADL) score of 9.1. The patients treated with efgartigimod improved their MG‐ADL score by an average of 5.5 points at 3 months (p < .001) and 7.1 points by 6 months (p < .001). Forty percent of patients achieved minimal symptom expression. Adverse events (AEs) were reported in 43.7% of patients on efgartigimod, the most common being mild infection (urinary tract infection and thrush). There were no serious AEs.Discussion: This study found efgartigimod to be efficacious, well tolerated, and safe in patients with MG. Efgartigimod should be considered as an add‐on therapy, a bridge therapy, or as a monotherapy if patients have difficulty tolerating other treatments.
- 21 November 2023
- Published by Wiley in Muscle & Nerve
- Vol. 69 (1) , 87-92
Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse events
Introduction/Aims: Efgartigimod is a neonatal Fc receptor blocker and was the first approved medication in its class for the treatment of generalized myasthenia gravis (gMG). As a novel therapy, little is known about the use of efgartigimod in clinical practice. This study aims to describe how efgartigimod is being incorporated into the current therapeutic landscape of MG.Methods: We reviewed the charts of 17 patients with gMG treated with efgartigimod at the University of Pennsylvania between January 2022 and June 2023.Results: Efgartigimod was selected mainly for patients who were treatment refractory, had side effects to other treatments, and/or required quick improvement in their symptoms. All patients had been previously treated with at least one medication for MG and had an average baseline Myasthenia Gravis Activities of Daily Living (MG‐ADL) score of 9.1. The patients treated with efgartigimod improved their MG‐ADL score by an average of 5.5 points at 3 months (p < .001) and 7.1 points by 6 months (p < .001). Forty percent of patients achieved minimal symptom expression. Adverse events (AEs) were reported in 43.7% of patients on efgartigimod, the most common being mild infection (urinary tract infection and thrush). There were no serious AEs.Discussion: This study found efgartigimod to be efficacious, well tolerated, and safe in patients with MG. Efgartigimod should be considered as an add‐on therapy, a bridge therapy, or as a monotherapy if patients have difficulty tolerating other treatments.
- 1 November 2014
- Published by Elsevier in Clinical Biomechanics
- Vol. 29 (9) , 1077-1080
The effect of ankle–foot orthosis plantarflexion stiffness on ankle and knee joint kinematics and kinetics during first and second rockers of gait in individuals with stroke
- 1 November 2014
- Published by Elsevier in Clinical Biomechanics
- Vol. 29 (9) , 1077-1080
The effect of ankle–foot orthosis plantarflexion stiffness on ankle and knee joint kinematics and kinetics during first and second rockers of gait in individuals with stroke
- Open Access
- 30 August 2014
- Published by Wiley in The Anatomical Record
- Vol. 298 (2) , 346-353
Age‐Related Difference in Postural Control During Recovery from Posterior and Anterior Perturbations
Decreased reactive postural responses in elderly adults may place them at increased risk for falls and related injuries. The first step in addressing the high rate of falls in the elderly population is to determine a baseline for postural response in healthy young and healthy elderly individuals. To determine these age‐related differences in reactive postural responses during recovery from posterior and anterior perturbations, we used the tether‐release method in conjunction with a motion analysis system to evaluate overall movement latencies, overall movement amplitude and velocity, and joint‐specific amplitude and velocity in healthy young (n = 10, mean age=25 ± 5) and healthy elderly participants (n = 10, mean age = 67 ± 6). During posterior perturbations, healthy elderly participants had increased recovery time (P = 0.01) and ratio of center of mass to step length (P = 0.013) when compared with young participants. Elderly participants also had decreased step length (P = 0.006), peak COM velocity (P = 0.01), peak knee flexion angle (P = 0.002), and decreased hip (P = 0.005) and knee (P = 0.0005) average angular velocity when compared with young participants. We conclude that these movement deficiencies at the hip and knee limited the length of the recovery step. With this restricted step, elderly participants could not achieve adequate mechanical advantage to counteract the displacement of their COM using a single step. During anterior perturbations, elderly participants did not exhibit any significant differences compared to young participants in overall movement variables. This understanding of postural responses in healthy individuals is clinically relevant to the development of rehabilitation programs for individuals at high fall risk. Anat Rec, 298:346–353, 2015.
- 30 August 2014
- Published by Wiley in The Anatomical Record
- Vol. 298 (2) , 346-353
Open AccessAge‐Related Difference in Postural Control During Recovery from Posterior and Anterior Perturbations
Decreased reactive postural responses in elderly adults may place them at increased risk for falls and related injuries. The first step in addressing the high rate of falls in the elderly population is to determine a baseline for postural response in healthy young and healthy elderly individuals. To determine these age‐related differences in reactive postural responses during recovery from posterior and anterior perturbations, we used the tether‐release method in conjunction with a motion analysis system to evaluate overall movement latencies, overall movement amplitude and velocity, and joint‐specific amplitude and velocity in healthy young (n = 10, mean age=25 ± 5) and healthy elderly participants (n = 10, mean age = 67 ± 6). During posterior perturbations, healthy elderly participants had increased recovery time (P = 0.01) and ratio of center of mass to step length (P = 0.013) when compared with young participants. Elderly participants also had decreased step length (P = 0.006), peak COM velocity (P = 0.01), peak knee flexion angle (P = 0.002), and decreased hip (P = 0.005) and knee (P = 0.0005) average angular velocity when compared with young participants. We conclude that these movement deficiencies at the hip and knee limited the length of the recovery step. With this restricted step, elderly participants could not achieve adequate mechanical advantage to counteract the displacement of their COM using a single step. During anterior perturbations, elderly participants did not exhibit any significant differences compared to young participants in overall movement variables. This understanding of postural responses in healthy individuals is clinically relevant to the development of rehabilitation programs for individuals at high fall risk. Anat Rec, 298:346–353, 2015.
- 1 January 2014
- Published by Elsevier in Gait & Posture
- Vol. 39 (1) , 638-640
Effects of dopamine replacement therapy on lower extremity kinetics and kinematics during a rapid force production task in persons with Parkinson disease
- 1 January 2014
- Published by Elsevier in Gait & Posture
- Vol. 39 (1) , 638-640
Effects of dopamine replacement therapy on lower extremity kinetics and kinematics during a rapid force production task in persons with Parkinson disease